A prospective randomised double-blind, double-dummy, placebo-controlled crossover study to determine whether Glucagon-like peptide-1 (GLP-1) stimulates or suppresses pancreatic exocrine function in health.

INTERVENTION: IV GLP‐1 (1.2 pmol/kg/min) infusion or placebo will be administrated to participants over 2 visits. Participants will receive a second IV containing either Secretin (75ng/kg/hr) and CCK (20ng/kg/hr) or placebo over 2 visits. Adherence of intervention will be monitored by both the clinical trial pharmacy and the researchers in the study to ensure the participants receive the correct treatment/placebo on any given trial day. Participants will be studied over 4 occasions, separated by at least 4 days. CONDITION: Critical Illness‐induced hyperglycaemia Hyperglycaemia Type 2 Diabetes PRIMARY OUTCOME: To determine whether GLP‐1 acutely stimulates pancreatic exocrine function in health. This will be assessed by peak duodenal bicarbonate concentration and pancreatic bicarbonate output. ; ; Peak duodenal amylase concentrations and amylase concentration area under the curve. SECONDARY OUTCOME: Changes in plasma amylase and lipase INCLUSION CRITERIA: Healthy Male volunteers between the ages of 18‐35